 |
Jean-Philippe Tripet, CFA Mr. Jean-Philippe Tripet is founder and Managing Partner of Aravis Venture, an internationally active venture fund focused on biotech investments. Jean-Philippe Tripet has over 15 years experience as portfolio manager and financial analyst. He has a degree in business administration from the University of Geneva, did graduate studies in San Diego (USA) and is a Chartered Financial Analyst. In 1994 Jean-Philippe Tripet co-founded the LO Fund that became one of the most successful healthcare funds in Europe under his leadership. He has supervised over 70 private biotech investments. Until 2001, he was a Senior Executive Vice-President and member of Group Management at Lombard Odier & Cie, Geneva. He founded Aravis Venture I in 2002. Since 1994 Jean-Philippe Tripet has participated actively in the launch and financing of many successful start-up companies such as Modex, NovImmune, Cytos, Genedata, Esbatech and Glycart. He is also Chairman of the board of directors of Evolva and Athelas, Vice Chairman of Symetis, and a director and Omeros. |
|
 |
Chu Swee Yeok Ms Swee-Yeok CHU is the Chief Executive Officer of Bio*One Capital, an investment management company of Singapore Economic Development Board (SEDB) which oversees global investments in the biotechnology and medical devices & technology. Bio*One manages one of the largest biomedical fund in Asia, and has some 60 portfolio companies worldwide. Apart from Merlion, Ms CHU's holds several other board directorship responsibilities, including S*BIO, an oncology drug discovery & development company; A-Bio Pharmaceuticals, a biologics process development & clinical contract manufacturing company, CombinatoRx Singapore, a joint-venture focusing on developing infectious disease drugs; Lonza Singapore, a joint-venture in commercial scale contract manufacturing; and the Novartis Institute of Tropical Diseases (NITD) in Singapore. |
|
 |
Tony Buss, PhD Dr Tony Buss is the President and CEO of MerLion Pharmaceuticals. He has held senior research and management positions with several major pharmaceutical and agrochemical companies, including 7 years with Pfizer, 6 years with Schering AG (both in the UK and Germany) and 13 years with GlaxoSmithKline. He joined the Centre for Natural Product Research, Singapore, in 2000 as Head of the Centre, before its incorporation as MerLion Pharmaceuticals Pte Ltd in 2002. Dr Buss is a graduate of the Royal Institute of Chemistry, London. He was awarded an MSc from the University of East Anglia in 1978 and received his PhD in 1981 from the University of Cambridge, England. He is also an Associate Professor at the National University of Singapore, Department of Chemistry. |
|
 |
Clemens Doppler, PhD Dr Doppler is a Managing Partner at Heidelberg Capital Asset Management GmbH. Prior to joining Heidelberg Capital in 2008, he was a director at 3i since 2000 and has 10 years of international business experience in the pharma and biotech industries. He held senior position at Boehringer Mannheim (now Roche) and was in the management team of Swiss Biotech company ANAWA Laboratories AG, which was successfully sold in 1997 to Phoenix International Life Science (now MDS Inc.). As well as serving on various boards, Dr Doppler is a member of the German biotech analyst association DVFA. He is also a fellow of the German Cancer Research Centre. Dr Doppler holds degrees in marketing and economics and a MSc and Ph.D. in molecular biology, chemistry and microbiology from the University of Heidelberg. |